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doi:10.1016/j.ejvs.2008.09.020Abstract Objectives: To evaluate data in the New Zealand Thoracic Aortic Stent database to
try and identify a scoring system that could predict 30-day mortality in patients undergoing
stenting of the descending thoracic aorta (TEVAR).
Design: Retrospective analysis of the New Zealand thoracic aortic stent database between
December 2001 and August 2007.
Materials and methods: The 30-day mortality of the 122 patients is 7.38% (nZ 9). Risk factors
were recorded based on the Society of Thoracic Surgeons (STS) risk score. Glasgowaneurysm score
was calculated and the pathology being treated analysed. Univariate analyisis was carried out.
Results: The mortality of three pathology groups was compared. 30-day mortality was 2.04%
(nZ 1) in the elective aneurysm group, 17.95% (nZ 7) in the complicated Stanford type B dissec-
tion group, and 0% (nZ 0) in the trauma group. Thirty-day mortality is significantly higher in the
dissection group compared with the elective aneurysm (pZ 0.02) and trauma (pZ 0.03) groups.
Themost frequent risk factors in the dissection group of patientswereperipheral vascular disease,
smokingandhypertension.Althoughpercentagemortality ishigherwith increasingGAS, the results
arenot statistically significant (pZ 0.34).No independent risk factorswere identified fromthe STS
risk score data.
Conclusion: No specific risk score system seems to be able to predict mortality in TEVAR patients.
ª 2008 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.3 364 0913; fax: þ64 3 364
nz (T.M. Buckenham).
ty for Vascular Surgery. PublisheIntroduction
The use of endovascular stent graft technology in the
treatment of diseases affecting the isthmus and descending
thoracic aorta is commonplace. It is generally believed that
patients undergoing endovascular repair of the thoracicd by Elsevier Ltd. All rights reserved.
Risk Mortality Endovascular Repair Thoracic Aorta 161aorta are likely to have better mortality and morbidity with
respect to the open surgical procedure. The European
Collaborators of Stent-graft Techniques for Thoracic Aortic
Aneurysm and Dissection Repair (EUROSTAR) and United
Kingdom Thoracic Endograft Registries had a combined
30-day mortality of 9.3%.1 When compared, endovascular
repair of degenerative thoracic aortic disease has been
shown to have lower 30-day mortality than surgery
(10.5% in the endovascular group, 15.1% in the open surgical
group, pZ 0.09).2
In cardiothoracic surgery, a number of scoring systems
have been developed to try and predict risk when under-
going coronary artery bypass surgery (CABG). Two of the
more widely used scoring systems include the Society of
Thoracic Surgeons (STS) risk score3,4 and the European
System for Cardiac Operative Risk Evaluation (Euro-
SCORE),5 both of which have similar predictive value when
compared with each other.6 These two scoring systems are
designed for use only in patients undergoing coronary
artery bypass surgery. Recently however, the Thoracic
Surgery Scoring System (Thoracoscore) has been developed
to assess risk in patients undergoing thoracic surgery in
general.7
Although these models are for surgical patients, it may
be possible to apply them to patients undergoing endo-
vascular procedures. Of the many other methods, the
Glasgow Aneurysm Score (GAS) system8 has been validated
in patients undergoing endovascular repair of abdominal
aortic aneurysms9 when used to analyse patients from the
EUROSTAR database.1 GAS is calculated at the bedside with
the formula: age (years)þ 7 (for myocardial disease e
previous infarct or angina)þ 10 (for cerebrovascular
disease e all grades of stroke including transient ischaemic
attacks)þ 14 (renal disease e creatinine above 133 mmol/l
or glomerular filtration rate below 50 ml/min). The strati-
fication is into one of three tertiles; less than 74.4, 74.4 to
83.6, or greater than 83.6.1
To our knowledge, no scoring system has been devised or
validated with regard to predicting the outcome of patients
undergoing an endovascular repair of the thoracic aorta. At
the time of conception of the New Zealand Thoracic Aortic
Stent (NZ TAS) database, the STS risk score was utilised in
order to capture as much risk information as possible. The
aim of this study was to analyse the data already collected
on the NZ TAS database to see if there were any identifiable
risk factors that may be related to an increase in 30-day
mortality. In particular, the patients were scored using the
STS and GAS systems to see if either of these could be used
in endovascular patients.
Patients and Methods
The New Zealand Thoracic Aortic Stent database (NZ TAS)
began data collection in December 2001. It involves
collaboration between six centres across New Zealand
carrying out endovascular repair of the thoracic aorta.
These include Auckland Hospital, Christchurch Hospital,
Dunedin Hospital, Greenlane Hospital in Auckland, Waikato
Hospital in Hamilton, and Wellington Hospital. A stand-
ardised form is filled in for each patient at the time of
implantation. This includes 19 risk factors based on the
Society of Thoracic Surgeons (STS) risk score (Fig. 1).Completed forms are sent to Christchurch Hospital where
the data is collated and added to the central electronic
database. In addition to this, a paper copy of all entries is
stored for back up. At the current time, permission is being
sought from all centres to carry out an audit to ensure
complete capture of all cases on the database.
The data from the STS score sheets of the 122 patients
on the database between December 2001 and August 2007
was analysed, together with patient age and the thoracic
aortic pathology being treated. If risk factor data was
missing, it was assumed to be normal for the purposes of
the analysis. The overall thirty-day mortality was 7.38%
(nZ 9). Causes of death included combinations of hae-
morrhage (nZ 3), myocardial infarct (nZ 1), cardiac
arrest (nZ 1), cerebrovascular accident (nZ 1), acute
renal failure (nZ 1), multi organ failure (nZ 2), compli-
cations of head injury (nZ 1), sepsis (nZ 1), recurrent
aneurysm rupture (nZ 1), acute type A dissection (nZ 1),
and oesophageal necrosis (nZ 1).
Univariate analysis of the STS risk scores was carried out
using the Fisher exact probability test to see if there were
any significant predictors of mortality in those patients who
died within 30 days of the endovascular procedure. In
addition, the Glasgow aneurysm score was calculated for
each patient and analysed to see if this was able to predict
30-day mortality.
Results
Of the 122 patients, STS data entry was complete in only
27 (22.1%) patients. Data entry was complete in only 8
(42.1%) of the 19 individual STS risk factors (Fig. 2).
Overall data capture for the 19 STS risk factors in the 122
patients was 94.13%. Amongst the 9 (7.38%) patients that
died within 30 days of the procedure, data collection was
complete in only one patient (Fig. 3). Overall data capture
for the 19 STS risk factors in these 9 patients was 90.64%.
The risk factors most poorly recorded were left ventricular
ejection fraction (32% data complete) and hyperlipidaemia
(75.4% data complete). If these two factors are excluded
however, data collection is reasonable at 98.89% in all
patients and 96.08% in the 9 patients that died within 30
days.
When pathology is evaluated, the three largest groups
in our series of 122 patients are the elective thoracic
aortic aneurysm cases (nZ 49, 40.16%), the Stanford type
B dissection cases (nZ 39, 31.97%), and the traumatic
aortic injury cases (nZ 24, 19.67%) (Table 1). Thirty-day
mortality in the elective aneurysm group was 2.04%
(nZ 1) in the traumatic aortic injury group 0% (nZ 0),
and in the dissection group it was 17.95% (nZ 7). There
is a statistically significant difference in 30-day mortality
between the dissection and elective aneurysm groups
(pZ 0.02) as well as between the dissection and trauma
groups (pZ 0.03). In addition, when comparing all of
these groups together, there is a statistically significant
difference in 30-day mortality (pZ 0.005). High mortality
is also seen in the thoracic aneurysm rupture group
(16.67%, nZ 1), but this group of patients is very small
(nZ 6) and the 30-day mortality is not significantly
different when compared to the other main pathological
groups.
Figure 1 Society of Thoracic Surgeons risk scoring sheet as used in the New Zealand Thoracic Aortic Stent database.
162 C.P. Day, T.M. BuckenhamAnalysis of the STS risk factors within the dissection
group did not demonstrate any statistical significance.
GAS could be calculated accurately in all but three patients
(96.7%). Overall data capture for the 4 GAS risk factors in the
122 patients on the NZ TAS database was 99.39%. Data capture
in the 9 patients that diedwithin 30 dayswas 100%. The results
are shown in Table 2. Although the raw data demonstratesincreased percentage 30-day mortality with increased GAS,
the results are not statistically significant (pZ 0.34).
Analysis of GAS with regard to the three main patho-
logical groups in our study; aneurysm, dissection, and
trauma is summarised in Table 3. This demonstrates a faint
trend toward higher GAS and increased mortality but the
results are not statistically significant.
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Figure 2 Risk factor data collection in all 122 patients in the New Zealand Thoracic Aortic Stent database.
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It is useful to develop risk assessment to predict operative
mortality and this process is well advanced in open heart
surgery.10,11 No such model exists for endoluminal repair of
the descending thoracic aorta. We have attempted to
predict mortality using two risk scoring systems developed
for other types of intervention, STS and GAS, but this was
made difficult by the small number of deaths in our data-
base. Further problems arose with the chosen scoring
systems. The STS scoring system is limited by its complexity
and requires investigations that may not be readily avail-
able, particularly in the emergency setting. Some of the
tests are not carried out routinely on acute patients, such
as echocardiography to determine left ventricular function
and blood tests for hyperlipidaemia, but these tests would0
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Figure 3 Risk factor data collection in the 9 patibe part of a normal work up in patients undergoing CABG
for which the STS risk score is designed.
Another limitation with our series is the small number of
deaths (30-day mortality is 7.38%, nZ 9), making it difficult
to perform any meaningful analysis with regard to risk
factors and death. The only significant results were the
relationships between pathology and 30-day mortality.
Patients with acute aortic dissection accounted for almost
80% of deaths in our series and had the highest 30-day
mortality of any group at almost 18%. This was significantly
different from the other two groups (trauma and aneu-
rysm), allowing us to conclude that acute aortic dissection
has a higher mortality after endovascular repair than
similar procedures for trauma and dilating disease.
Our 30-day mortality is greater than that reported in
a study by Sandroussi et al.12 Their 30-day mortality afterGI
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ents that died within 30 days of the procedure.
Table 3 Glasgow aneurysm score in the three main
pathological groups
Aetiology <74.4 74.4e83.6 >83.6 Total
Aneurysm n 30 15 4 49
% 61.22 30.61 8.16 43.75
Dissection n 28 6 5 39
% 71.79 15.38 12.82
Trauma n 22 2 0 24
% 91.67 8.33 0
Total n 80 23 9 112
% 71.43 20.54 8.04 100.00
Table 1 Aetiology with survival and 30-day mortality
Survived 30-day mortality Total
Aneurysm elective n 48 1 49
% 97.96 2.04
Aneurysm rupture n 5 1 6
% 83.33 16.67
Dissection n 32 7 39
% 82.05 17.95
Mycotic aneurysm n 4 0 4
% 100 0
Trauma n 24 0 24
% 100 0
Total n 113 9 122
% 92.67 7.38
164 C.P. Day, T.M. Buckenhamendovascular thoracic aortic repair was 12.5%. All of these
patients had Stanford type B aortic dissection. Mortality is
also high in surgical patients with type B dissection
reported at 14.5% in the study by Chan et al.13 Predictors of
early mortality in these series included hypertension, leak,
acute renal failure and chronic obstructive pulmonary
disease.13e15 Of the seven patients who died after
endoluminal repair of dissection in our study, five (71.4%)
patients had hypertension. One patient had chronic
obstructive pulmonary disease but none had acute renal
failure or evidence of extravasation.
In summary, the STS scoring system (specifically devel-
oped to predict mortality in patients undergoing CABG) has
not been validated with regard to endovascular thoracic
stenting. Our data analysis shows that this scoring system is
not predictive in our patient group, but this may change
with increasing numbers.
GAS has been validated in patients undergoing endo-
vascular repair of the abdominal aorta in patients on the
EUROSTAR database.9 It has the advantages over the STS
system including simplicity, calculation at the bedside,
and, in our database, there was almost complete data
capture. The main limitation when using GAS in our patents
is the tertiles used by Biancari et al. One reason for this is
the median GAS score is much lower in our series (68.5
compared to 78.8) which places patients in the lowest
(<74.4) GAS tertile referred to by Biancari et al.9 Another
reason is the lower median age of the patients in our series
(65 compared to 72.7) that will, once again, put patients in
the lower tertile. One reason for the lower age is ourTable 2 Glasgow aneurysm score and 30-day mortality
GAS Survived 30-day mortality Total
<74.4 n 78 5 83
% 93.98 6.02
74.4e83.6 n 24 2 26
% 92.31 7.69
>83.6 n 11 2 13
% 84.62 15.38 10.66
Total n 113 9 122
% 92.62 7.38 100.00inclusion of trauma patients who tend to be young, with
median age 24.4 years. The GAS is still lower even when
considering only those patients with aneurysm of the
descending thoracic aorta (median 74). Ultimately, GAS
tertiles as they stand may need to be modified to reflect
these differences.
In conclusion, our database demonstrates significantly
higher 30-day mortality for patients undergoing endovas-
cular repair of acute type B thoracic aortic dissection
compared to all other pathologies treated. Neither the STS
nor GAS risk score systems seem to be able to predict
mortality in TEVAR patients. Data collection will continue in
order to allow analysis with a larger cohort of patients
when available.
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